InDex Pharmaceuticals Holding AB (publ), a Sweden-based pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options, announced on Friday an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod.
The result of the dose selection is likely to be provided in the fourth quarter of 2023. The company will have finalised the evaluation of consequences on the overall development timeline, including top line results in CONCLUDE, at that point in time.
The CONCLUDE study, a phase III study, is assessing the first-in-class TLR9 agonist cobitolimod as a novel treatment for subjects with moderate to severe left-sided ulcerative colitis. It includes around 440 subjects and is being carried out at various clinics in more than 30 countries in Europe, the Americas and the Asia-Pacific region.
FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial
CSL opens Massachusetts research and development centre
BJ Bioscience signs clinical trial collaboration and supply agreement with Merck
DermBiont Touts Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel
Athersys Reports on Type B Meeting with the US FDA
Incyte receives Japanese approval for Pemazyre to treat myeloid/lymphoid neoplasms